Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: J Clin Virol. 2020 Apr 11;127:104344. doi: 10.1016/j.jcv.2020.104344

Table 2:

Results from HIV assays b in early infection samples characterized by Fiebig stage

n with HIV test result: c
Fiebig Stage: RNAa Architect Determine GS+O Geenius HIV-1 WB G4 LAB G4 POC
n Pos Ag/Ab-R Ag-R Ag/Ab-R Ab-R IgG/IgM R Neg Ind Pos Interpretation IgG R IgG R
Eclipse 5 0 0 0 0 0 0 5 0 0 Neg 0 0
I 4 4 0 0 0 0 0 4 0 0 Neg 0 0
II 4 4 4 3 0 0 0 4 0 0 Neg 0 0
III 6 6 6 4 2 3 6 4 2 0 Neg 1 0
IV 13 13 13 7 6 11 12 4 5 4 HIV-1 Ind 7 2
V 6 6 6 0 0 6 6 0 0 6 HIV-1 Posd 6 6
a

Plasma testing for HIV-1 RNA included results from either Roche CAP/CTM or Roche Amplicor Monitor.

b

Plasma testing: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, Geenius HIV-1/2 Supplemental Assay (IgG), HIV-1 WB: Cambridge Biotech HIV-1 Western blot Kit or Bio-Rad Genetic Systems HIV-1 (IgG), GS+O: GS HIV-1/HIV-2 PLUS O EIA (IgG/IgM), G4 LAB: MedMira Reveal G4 LAB S/P (IgG Rapid Test). Blood testing: G4 POC: MedMira Reveal G4 POC (IgG Rapid Test).

c

Neg: negative; Ind: indeterminate; Pos: positive; R: reactive; Ag: antigen; Ab: antibody. Geenius results: Neg: Ab-Neg; Ind: HIV-1 indeterminate; Pos: HIV-1 positive.

d

HIV-1 positive (p31-).